386 related articles for article (PubMed ID: 17483538)
21. Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index.
Parini R; Rigoldi M; Santus F; Furlan F; De Lorenzo P; Valsecchi G; Concolino D; Strisciuglio P; Feriozzi S; Di Vito R; Ravaglia R; Ricci R; Morrone A
Clin Genet; 2008 Sep; 74(3):260-6. PubMed ID: 18445046
[TBL] [Abstract][Full Text] [Related]
22. Fabry disease: focus on cardiac manifestations and molecular mechanisms.
Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C
Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642
[TBL] [Abstract][Full Text] [Related]
23. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
[TBL] [Abstract][Full Text] [Related]
24. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
25. Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy.
Kovacevic-Preradovic T; Zuber M; Attenhofer Jost CH; Widmer U; Seifert B; Schulthess G; Fischer A; Jenni R
Eur J Echocardiogr; 2008 Nov; 9(6):729-35. PubMed ID: 18490303
[TBL] [Abstract][Full Text] [Related]
26. Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.
Putko BN; Wen K; Thompson RB; Mullen J; Shanks M; Yogasundaram H; Sergi C; Oudit GY
Heart Fail Rev; 2015 Mar; 20(2):179-91. PubMed ID: 25030479
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.
Kampmann C; Perrin A; Beck M
Orphanet J Rare Dis; 2015 Sep; 10():125. PubMed ID: 26416388
[TBL] [Abstract][Full Text] [Related]
28. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
[TBL] [Abstract][Full Text] [Related]
29. Enzyme replacement therapy and renal function in 201 patients with Fabry disease.
Schwarting A; Dehout F; Feriozzi S; Beck M; Mehta A; Sunder-Plassmann G;
Clin Nephrol; 2006 Aug; 66(2):77-84. PubMed ID: 16939062
[TBL] [Abstract][Full Text] [Related]
30. Cardiac manifestations of Anderson-Fabry disease in heterozygous females.
Kampmann C; Baehner F; Whybra C; Martin C; Wiethoff CM; Ries M; Gal A; Beck M
J Am Coll Cardiol; 2002 Nov; 40(9):1668-74. PubMed ID: 12427421
[TBL] [Abstract][Full Text] [Related]
31. Clinical study of left ventricular structure and function in patients with Anderson-Fabry disease before and after enzyme replacement therapy.
Huang S; Wang J; Zhang W; Gao F; Chen Y; Shui W; Xing X; Chen S; Mu Y
J Clin Ultrasound; 2024 Jan; 52(1):20-29. PubMed ID: 37883130
[TBL] [Abstract][Full Text] [Related]
32. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
[TBL] [Abstract][Full Text] [Related]
33. Effects of Agalsidase Alfa Enzyme Replacement Therapy on Left Ventricular Hypertrophy on Electrocardiogram in a Female Patient with Fabry Disease.
Nakamura K; Morita H; Takaya Y; Saito Y; Miyoshi T; Morinaga H; Sugiyama H; Wada J; Ito H
Int Heart J; 2023 May; 64(3):502-505. PubMed ID: 37197914
[TBL] [Abstract][Full Text] [Related]
34. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy.
Messalli G; Imbriaco M; Avitabile G; Russo R; Iodice D; Spinelli L; Dellegrottaglie S; Cademartiri F; Salvatore M; Pisani A
Radiol Med; 2012 Feb; 117(1):19-28. PubMed ID: 21744250
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease.
Tsujiuchi M; Ebato M; Maezawa H; Mizukami T; Nogi A; Ikeda N; Iso Y; Suzuki H
Int Heart J; 2019 Jan; 60(1):208-214. PubMed ID: 30464119
[TBL] [Abstract][Full Text] [Related]
36. Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey.
Kleinert J; Dehout F; Schwarting A; de Lorenzo AG; Ricci R; Kampmann C; Beck M; Ramaswami U; Linhart A; Gal A; Houge G; Widmer U; Mehta A; Sunder-Plassmann G
Kidney Int; 2005 May; 67(5):1955-60. PubMed ID: 15840043
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Talbot AS; Lewis NT; Nicholls KM
Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
[TBL] [Abstract][Full Text] [Related]
38. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.
Mehta A; Ricci R; Widmer U; Dehout F; Garcia de Lorenzo A; Kampmann C; Linhart A; Sunder-Plassmann G; Ries M; Beck M
Eur J Clin Invest; 2004 Mar; 34(3):236-42. PubMed ID: 15025684
[TBL] [Abstract][Full Text] [Related]
39. Fabry in the older patient: Clinical consequences and possibilities for treatment.
Lidove O; Barbey F; Niu DM; Brand E; Nicholls K; Bizjajeva S; Hughes DA
Mol Genet Metab; 2016 Aug; 118(4):319-25. PubMed ID: 27221354
[TBL] [Abstract][Full Text] [Related]
40. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.
Ries M; Clarke JT; Whybra C; Timmons M; Robinson C; Schlaggar BL; Pastores G; Lien YH; Kampmann C; Brady RO; Beck M; Schiffmann R
Pediatrics; 2006 Sep; 118(3):924-32. PubMed ID: 16950982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
